Table 1. Main characteristics of the 27 patients with LCH divided in two groups according to the presence of either MRI alterations specific for ND-LCH (Group 1) or only of risk factors for ND-LCH (Group 2).
| Group 1N = 17 | Group 2N = 10 | Difference(95% confidence interval)p-value | |
|---|---|---|---|
| Gender | 9 M, 8 F | 7 M, 3 F | |
| Median age at study entry (range) | 8.2 years(1.7 to 27.5 years;quartiles: 5, 8.2, 11.7 years) | 10.2 years(3.7 to 16.4 yearsquartiles: 5.8, 10.2, 14.8 years) | -2.02 years(-8.97;4.6)p = 0.688 |
| Median time between the onset of LCH and the first MRI evaluation | 4.2 years | 2.4 years | 1.8 years(-1.3;5.1)p = 0.248 |
| Median time between the l onset of LCH and the first observation of ND-LCH at MRI | 4.2 years(quartiles: 0.8; 2.5; 4.2; 6.5; 14.5 years). | n.a. | |
| Median age at onset s of LCH | 2 years(range, 4 months -18 years;quartiles: 0.9, 2 and 3.3 years) | 5.5 years(range, 18 months -15 years; quartiles: 3.2, 5.5 and 9.5 years) | -3.years(-8.4;-0.7)p = 0.024 |
| Multisystem vs. Single system | 13 (76%) vs. 4 | 6 (60%) vs. 4 | 16%(-20;53%)p = 0.365 |
| Reactivating or chronic active LCH | 15 (88%) | 6 (60%) | 28%(6;62%)p = 0.088 |
| Risk lesions for ND-LCH: Diabetes insipidus / Craniofacial lesions | 11 / 6 | 6 / 5* | Odds Ratio 1.53(0.32; 7.37)p = 0.591 |
| Previous chemotherapy ongoing | 15 (88%)7 (41%) | 9(90%)4(40%) | -2%(-26; 22%)p = 0.888/1%(-37; 39%)p = 0.952 |
This is the Table 1 footnote.
* one patient had both risk factors